SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

INVITROCUE LIMITED (IVQ)

Suspended from ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

 FROMTO
INVITROCUE LIMITED25/01/2016
BUNURU CORPORATION LIMITED05/06/201525/01/2016
EHG CORPORATION LIMITED07/11/201205/06/2015
ELLECT HOLDINGS LIMITED16/02/200907/11/2012
INTELLECT HOLDINGS LIMITED16/02/2009

Shareholder links

 

REGISTRY:

Automic Registry Services Level 5 126 Phillip Street Sydney NSW 2000

Tel : +61 (2) 8072 1400 or 1300 288 664 (within Australia)
Fax :
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000IVQ8
Address: Level 2, 350 Kent Street, Sydney, NSW 2000
Tel:  + 61 8 9367 8133 Fax: +61 8 9367 8812

Date first listed: 14/12/1994
Company Secretary: Mr. Chow-Yee Koh
Sector: Technology Hardware & Equipment Industry Group: XIJ
Activities: Electronic product development and distribution

Through its 70% owned subsidiary company Invivocue Pte Ltd, IVQ has completed development of ACE-2 Humanised Immune Mice platform. Currently under validation study with Duke NUS in Singapore. Expected scientific publication with validation data in coming months. In research partnership with Pangaea Oncology SA, IVQ secured first commercial pilot contract to supply ACE-2 HiMice to Pharma Mar SA.

24/09/2020

Shareholders in this company should consider crystallising a capital loss in 2020/21 by selling their worthless shares, which they can achieve online by entering transaction details here. While this usually makes good economic sense, we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person.

13/08/2020

The company lodges its Appendix 4C - quarterly.

31/07/2020

The company releases its 4C Commentaries and Management Updates.

01/05/2020

The company lodges its Appendix 4C - quarterly.

29/04/2020

Invitrocue has successfully registered CE Mark for its Onco-PDO Cancer Test. The CE Mark allows the test to be sold in the European Economic Region.

21/04/2020

Memorandum of Understanding entered into for the establishment of Invitrocue Brazil, a joint venture with Brazilian partners. Invitrocue Brazil intends to offer Invitrocue's proprietary personalised cancer test to private-paying patients in Brazil and the rest of Latin America. Test work will be carried out in lab in Brazil that will be fully funded by local partners.

11/02/2020

The company releases its 4C Commentaries and Management Updates. The highlights are as follows: 4C Commentaries - Collection for the quarter of SGD$338,000 is higher compared to previous quarter of SGD$181,000; and Combined Onco-PDO and HiMice business continues to attract new funding. Management Updates - US$750,000 of convertible notes placed in Dec 2019; Additional funding of up to US$10 million conditionally agreed; Integrating Onco-PDOand HiMice in new service platform that has clinical and pharmacology applications; German validation study started final Cohort 2; Secured major client for Pharmacology services.

05/02/2020

The company lodges its Appendix 4C - quarterly.

30/01/2020

The company issues a response to ASX query.

30/12/2019

The company issues a cleansing prospectus for the offer of 5 shares at an issue price of $0.20 per share to raise $1.

17/12/2019

The company releases a notification of a proposed issue of securities.

16/12/2019

The company has entered into a subscription agreement with ChinaLink Limited of up to US$10 million in 2 tranches and has formed a joint venture with the investor. The first 25 cases expected to be completed in Q1 2020. The validation study is expected to last 1 to 2 years, and the Investment spanning over 2 or more financial years. The investor will subscribe for the company shares at the lower of A$0.045 per share or the VWAP of the Shares over 5 trading days prior to completion of each tranche of the subscription for shares.

06/12/2019

The company releases the results of its meeting.

27/11/2019

The company lodges its Appendix 4C - quarterly.

31/10/2019

The company's AGM will be held at the office of Invitrocue Pte Ltd, 11 Biopolis Way, Helios #12-07/08, Singapore 138667 on 27 November 2019 commencing at 4.00pm (Singapore time).

28/10/2019

The company has today received notices of resignations from Professor Hanry Yu, Mr Kit Wei Lui and Ms Ee Ting Ng as directors of the company. As the directors whom are the subject of the general meeting resolutions have resigned, there is no resolution to move at the meeting. Accordingly, in accordance with clause 9.7 of the company's constitution, the board has determined to cancel the meeting.

15/10/2019

The company releases the results of its meeting.

11/10/2019

The company releases an Appendix 4G.

02/10/2019

The company releases its Corporate Governance Statement.

02/10/2019

The company lodges its Appendix 4E and Annual Report.

02/10/2019

The company establishes Hong Kong Laboratory. This will provide greater access to oncologists and patients in Greater China region of mainland China, Hong Kong and Macau. This will be used for R&D and commercial purposes. Lab is currently being equipped and will be completed and operational by November 2019. Hired key staff for the lab including a General Manager.

27/09/2019

The company provides the following update: Commenced clinical validation with Klinikum Rechts der Isar der Technischen Universität München, Comprehensive Cancer Center Munich, Germany; Study uses IVQ's personalised oncology approach to evaluate the effect of cancer drugs on the patients' own unique tumour cells in the lab; Results from cohort 1 of the study are expected within the next quarter and initial results are positive.

24/09/2019

The company releases the response by Non-Executive Directors Prof Hanry Yu and Mr Kit Wei Lui to the Notice of Meeting (released on 17 September 2019) in accordance with the right of directors to put their case to members pursuant to section 203D(4) of the Corporations Act.

24/09/2019

Notice is hereby given that a General Meeting of Shareholders of the Company be called at the request of Dr Steven Fang, Dr Andreas Lindner, Dr Gary Pace and Mr Geoffrey Thomas severally as directors of Invitrocue Limited. The meeting will be held on 18 October 2019 at 2.00pm Perth time at The Executive Centre, Room 25A, Level 25, 108 St Georges Terrace, Perth WA 6000, Australia.

17/09/2019

In relation to the notice of meeting released by three directors which details the removal of Dr. Boon Sing Fang as director, Dr. Boon Sing Fang issues a response in accordance with the right of directors to put their case to members.

16/09/2019

The company makes a correction to the incorrect registered address indicated in the proxy form released this morning.

13/09/2019

The company provides an updated proxy form for the notice of meeting.

13/09/2019

On 11 September 2019, the company received a further Notice of Intention pursuant to Section 203D(2) of the Corporations Act from directors Prof Hanry Yu, Ms Ee Ting Ng and Mr Kit Wei Lui to move a resolution at a general meeting for the removal of Geoffrey David Edwin Thomas as director of the company.

12/09/2019

The company releases a notice of general meeting. The meeting will be held at the offices of Macpherson Kelley, Level 21, 20 Bond Street, Sydney 2000 on 11 October 2019 at 11:00 am, Sydney time.

11/09/2019

In relation to the S203D notices, the directors are having ongoing dialogues with the parties involved.

06/09/2019

The company issues a cleansing statement. It has issued and allotted 16,096,667 shares and 3,219,334 options to investors via private placements.

23/08/2019

The company has not paid their annual listing fees in respect of the year ending 30 June 2020 but the securities are already suspended from official quotation.

22/08/2019

The securities of Invitrocue Limited will be suspended from quotation immediately under Listing Rule 17.3.

12/08/2019

name changed from Bunuru Corporation Limited

25/01/2016

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    22/11/2018Chow-Yee Koh12,000$0.080$956

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Steven FangChairman, Executive Director15/01/2016
    William UrquhartNon Exec Director30/08/2013
    Andreas LindnerNon Exec Director07/02/2018
    Louis SchurmannNon Exec Director22/08/2013
    Antony EatonNon Exec Director18/09/2019
    Chow-Yee KohExecutive Director18/05/2015

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Geoffrey ThomasNon Exec Director09/09/201902/03/2020
    Ee Ting NgIndependent Director18/05/201515/10/2019
    Kit LuiNon Exec Director11/03/201915/10/2019
    Hanry YuNon Exec Director24/03/201615/10/2019
    Gary PaceIndependent Director23/10/201818/09/2019
    Jamie KhooNon Exec Director18/05/201511/03/2019
    David SuttonNon Exec Chairman22/08/201318/05/2015
    Greg CornelsenNon Exec Director15/10/201230/08/2013
    Steven NicolsNon Exec Chairman15/10/201222/08/2013
    Adam BlumenthalNon Exec Director15/10/201222/08/2013
    Warren McLelandNon Exec Chairman21/04/200515/10/2012
    Allan SullivanNon Exec Director28/08/200715/10/2012

    Date of first appointment, title may have changed.